Consensus ORIC Pharmaceuticals, Inc. Börse Stuttgart

Stocks

4TZ

US68622P1093

Biotechnology & Medical Research

Market Closed - Börse Stuttgart 15:56:01 2026-10-14 EDT			5-day change	1st Jan Change
10.35 ^EUR	+2.78%		-4.46%	+45.94%

09-15	ORIC Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
08-28	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT

3f440aa3a80c5c01e.ELoaEF6Tp6bNDa-9eqLlgz-8TDa4GXNxqIsCqvfSm8g.RIJMaiin5s__SZ_3HMWQs3vbPnrZdRdDnf1487C347pq9mtIbtXW0olU-g~603bf97f7f44956de09de9ba910a25d8

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

10-05	Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target	MT
09-23	BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target	MT
04-01	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
01-07	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
11-14	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
25-05-06	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
24-10-31	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
24-10-31	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
24-09-06	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
24-08-13	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
24-03-27	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
24-03-21	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
24-03-12	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
24-03-01	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
24-02-26	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
23-12-13	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
23-12-12	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
23-10-26	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
23-10-24	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23-10-23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
23-09-22	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
23-08-16	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
23-08-15	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
23-05-10	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
23-04-05	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
ORIC PHARMACEUTICALS, INC.	-	-	-	-
WUXI APPTEC CO., LTD.				+21.23%
ARGENX SE				+41.64%
LONZA GROUP AG				+21.73%
IQVIA HOLDINGS INC.				+13.73%
REVOLUTION MEDICINES, INC.				+37.52%
BEONE MEDICINES AG				+24.77%
CELLTRION, INC.				+49.05%
WUXI BIOLOGICS (CAYMAN) INC.				+16.02%
BIONTECH SE				+30.78%
Average				+28.50%
Weighted average by Cap.				+27.84%